{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:27:07Z","timestamp":1717547227584},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00105-024-05351-6","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T16:01:46Z","timestamp":1716825706000},"page":"451-458","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kutane Nebenwirkungen onkologischer Systemtherapien","Cutaneous adverse events to systemic anticancer therapies"],"prefix":"10.1007","volume":"75","author":[{"given":"Selma","family":"Ugurel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"5351_CR1","unstructured":"(2017) Common Terminology Criteria for Adverse Events (CTCAE) Version\u00a05.0. Publish Date: November\u00a027. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Zugegriffen: 5. Apr. 2024"},{"key":"5351_CR2","doi-asserted-by":"publisher","unstructured":"Numakura, Cancer Biology & Therapy 2024, Vol. 25, No. 1, 2312602, https:\/\/doi.org\/10.1080\/15384047.2024.2312602","DOI":"10.1080\/15384047.2024.2312602"},{"key":"5351_CR3","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen \u2013 Langversion 1.3, 2020, AWMF Registernummer: 032\/054OL. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/supportive-therapie\/. Zugegriffen: 5. Apr. 2024"},{"issue":"35","key":"5351_CR4","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf\u00a0SL, Qin\u00a0R, Menon\u00a0SP, Rowland\u00a0KM\u00a0Jr, Thomas\u00a0S, Delaune\u00a0R, Christian\u00a0D, Pajon\u00a0ER\u00a0Jr, Satele\u00a0DV, Berenberg\u00a0JL, Loprinzi\u00a0CL; North Central Cancer Treatment Group Study N05C5 (2010) Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28(35):5182\u20135187","journal-title":"J Clin Oncol"},{"issue":"22","key":"5351_CR5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","volume":"33","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz\u00a0RD, Gencer\u00a0D, Schulz\u00a0H, Stahl\u00a0M, Hegewisch-Becker\u00a0S, Loeffler\u00a0LM, Kronawitter\u00a0U, Bolz\u00a0G, Potenberg\u00a0J, Tauchert\u00a0F, Al-Batran\u00a0SE, Schneeweiss\u00a0A (2015) Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 33(22):2444\u20132449","journal-title":"J Clin Oncol"},{"issue":"8","key":"5351_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren\u00a0Z, Zhu\u00a0K, Kang\u00a0H, Lu\u00a0M, Qu\u00a0Z, Lu\u00a0L, Song\u00a0T, Zhou\u00a0W, Wang\u00a0H, Yang\u00a0W, Wang\u00a0X, Yang\u00a0Y, Shi\u00a0L, Bai\u00a0Y, Guo\u00a0X, Ye\u00a0SL (2015) Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(8):894\u2013900","journal-title":"J Clin Oncol"},{"key":"5351_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.09.012","volume":"140","author":"YS Lee","year":"2020","unstructured":"Lee\u00a0YS, Jung\u00a0YK, Kim\u00a0JH, Cho\u00a0SB, Kim\u00a0DY, Kim\u00a0MY, Kim\u00a0HJ, Seo\u00a0YS, Yoon\u00a0KT, Hong\u00a0YM, Lee\u00a0JH, Lee\u00a0HW, Yim\u00a0HJ, Jang\u00a0BK, Jang\u00a0ES, Jang\u00a0JY, Hwang\u00a0SY (2020) Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A\u00a0multicenter, randomised, double-blind controlled study. Eur J Cancer 140:19\u201327. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.012","journal-title":"Eur J Cancer"},{"key":"5351_CR8","first-page":"JCO2301730","volume":"27","author":"A Santhosh","year":"2024","unstructured":"Santhosh\u00a0A, Sharma\u00a0A, Bakhshi\u00a0S, Kumar\u00a0A, Sharma\u00a0V, Singh\u00a0PM, Pramanik\u00a0R, Gogia\u00a0A, Prakash Prasad\u00a0C, Sehgal\u00a0T, Gund\u00a0S, Dev\u00a0A, D\u2011TORCH Trial Investigators (2024) Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a\u00a0double-blind randomized controlled trial. J\u00a0Clin Oncol 27:JCO2301730","journal-title":"J Clin Oncol"},{"issue":"5","key":"5351_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00520-013-2095-x","volume":"22","author":"AL McCarthy","year":"2014","unstructured":"McCarthy\u00a0AL, Shaban\u00a0RZ, Gillespie\u00a0K, Vick\u00a0J (2014) Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial. Support Care Cancer 22(5):1375\u20131383. https:\/\/doi.org\/10.1007\/s00520-013-2095-x","journal-title":"Support Care Cancer"},{"issue":"4","key":"5351_CR10","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert\u00a0C, Sibaud\u00a0V, Mateus\u00a0C, Verschoore\u00a0M, Charles\u00a0C, Lanoy\u00a0ERB (2015) Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16(4):e181\u2013e189. https:\/\/doi.org\/10.1016\/S1470-2045(14)71133-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"5351_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/jjco\/hym042","volume":"37","author":"J Hong","year":"2007","unstructured":"Hong\u00a0J, Park\u00a0SH, Choi\u00a0SJ, Lee\u00a0SH, Lee\u00a0KC, Lee\u00a0JI, Kyung\u00a0SY, An\u00a0CH, Lee\u00a0SP, Park\u00a0JW, Jeong\u00a0SH, Nam\u00a0E, Bang\u00a0SM, Cho\u00a0EK, Shin\u00a0DB, Lee\u00a0JH (2007) Nail toxicity after treatment with docetaxel: a\u00a0prospective analysis in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 37(6):424\u2013428. https:\/\/doi.org\/10.1093\/jjco\/hym042","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"5351_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","volume":"67","author":"BC Garden","year":"2012","unstructured":"Garden\u00a0BC, Shenhong\u00a0W, Lacouture\u00a0ME (2012) The risk of nail changes with epidermal growth factor receptor inhibitors: a\u00a0systematic review of the literature and meta-analysis. J\u00a0Am Acad Dermatol 67(3):400\u2013408. https:\/\/doi.org\/10.1016\/j.jaad.2011.10.009","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5351_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/era.13.30","volume":"13","author":"ME Lacouture","year":"2013","unstructured":"Lacouture\u00a0ME, Schadendorf\u00a0D, Chu\u00a0CY, Uttenreuther-Fischer\u00a0M, Stammberger\u00a0U, O\u2019Brien\u00a0D, Hauschild\u00a0A (2013) Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 13(6):721\u2013728. https:\/\/doi.org\/10.1586\/era.13.30","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"5351_CR14","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","volume":"23","author":"F Scott\u00e9","year":"2005","unstructured":"Scott\u00e9\u00a0F, Tourani\u00a0JM, Banu\u00a0E, Peyromaure\u00a0M, Levy\u00a0E, Marsan\u00a0S, Magherini\u00a0E, Fabre-Guillevin\u00a0E, Andrieu\u00a0JM, Oudard\u00a0S (2005) Multicenter study of a\u00a0frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J\u00a0Clin Oncol 23(19):4424\u20134429. https:\/\/doi.org\/10.1200\/JCO.2005.15.651","journal-title":"J Clin Oncol"},{"issue":"7","key":"5351_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/cncr.23333","volume":"112","author":"F Scott\u00e9","year":"2008","unstructured":"Scott\u00e9\u00a0F, Banu\u00a0E, Medioni\u00a0J, Levy\u00a0E, Ebenezer\u00a0C, Marsan\u00a0S, Banu\u00a0A, Tourani\u00a0JM, Andrieu\u00a0JM, Oudard\u00a0S (2008) Matched case-control phase\u00a02\u00a0study to evaluate the use of a\u00a0frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112(7):1625\u20131631. https:\/\/doi.org\/10.1002\/cncr.23333","journal-title":"Cancer"},{"issue":"8","key":"5351_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture\u00a0ME, Anadkat\u00a0MJ, Bensadoun\u00a0RJ, Bryce\u00a0J, Chan\u00a0A, Epstein\u00a0JB, Eaby-Sandy\u00a0B, Murphy\u00a0BA, MASCC Skin Toxicity Study Group (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079\u20131095. https:\/\/doi.org\/10.1007\/s00520-011-1197-6","journal-title":"Support Care Cancer"},{"issue":"9","key":"5351_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen\u00a0A, Alter\u00a0M, Schenck\u00a0F, Satzger\u00a0I, V\u00f6lker\u00a0B, Kapp\u00a0A, Gutzmer\u00a0R (2010) The hand-foot-syndrome associated with medical tumor therapy\u2014classification and management. J\u00a0Dtsch Dermatol Ges 8(9):652\u2013661. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07449.x (English, German)","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05351-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05351-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T11:47:27Z","timestamp":1717501647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05351-6"}},"subtitle":["Hand-Fu\u00df-Syndrom und Nagelver\u00e4nderungen","Hand\u2013foot syndrome and nail changes"],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5351"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05351-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"10 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Ugurel erkl\u00e4rt, dass sie Forschungsunterst\u00fctzung von Bristol-Myers Squibb und Merck Serono, Referenten- und Beratungshonorare von Bristol-Myers Squibb, Merck Sharp & Dohme, Merck Serono und Novartis sowie Unterst\u00fctzung f\u00fcr Tagungen und Reisen von Almirall, Bristol-Myers Squibb, IGEA Clinical Biophysics, Merck Sharp & Dohme, Novartis, Pierre Fabre und Sun Pharma au\u00dferhalb der eingereichten Arbeit erh\u00e4lt. C.\u00a0Pf\u00f6hler: Vortragshonorare, Unterst\u00fctzung f\u00fcr Beratung und Reisen von: MSD, BMS, Roche, Novartis, AbbVie, Sanofi, Merck Serono, Sun Pharma, Pierre Fabre, AMGEN, LEO und Allery Therapeutics (au\u00dferhalb der eingereichten Arbeit). R.\u00a0Gutzmer: Forschungsunterst\u00fctzung (an Institution): Novartis, SUN-Pharma, Amgen, Sanofi\/Regeneron, Merck Serono, Almirall-Hermal, Kyowa Kirin. Honorare f\u00fcr Vortr\u00e4ge und Beratung (pers\u00f6nlich): Bristol-Myers Squibb, Novartis, MSD, Almirall-Hermal, Amgen, Merck Serono, SUN-Pharma, Pierre-Fabre, Sanofi\/Regeneron, 4SC, Immunocore, Delcath. Unterst\u00fctzung f\u00fcr Kongressteilnahme (pers\u00f6nlich): Pierre Fabre, SUN-Pharma, Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}